findmyKOL

Jonathan Rosenberg, MD

Enriched profile

Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz, Jr. Chair · Memorial Sloan Kettering Cancer Center

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyMedical OncologyFocusProstate Cancer+1
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2012–2024

Jonathan Rosenberg is Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz, Jr. Chair at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 817 publications with 51,894 citations (h-index 85); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Jonathan Rosenberg as a Highly Cited Researcher (Cross-Field, 2021-2025).

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Jonathan Rosenberg, MD, is Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. The public record shows 817 publications with 51,894 citations (h-index 85), centered on Prostate Cancer, Bladder / Urothelial Cancer. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 21 companies, 2 NIH-funded awards (2012–2024).

  • Most recent indexed publication: 2026 · Clinical cancer research
  • Top research focus: Prostate Cancer
  • 5 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 21 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Bladder / Urothelial Cancer4 trialsProstate Cancer2 trialsUrethral Neoplasms2 trialsUreteral Neoplasms2 trialsCarcinoma, Transitional Cell1 trialPelvic Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Prostate CancerBladder / Urothelial Cancer

Drugs & molecules

across trials, industry payments and publications
Padcevgeneric · EnfortumabClinical trialsIndustry payments26Publications5Imfinzigeneric · DurvalumabClinical trialsIndustry payments3Publications2Imjudogeneric · TremelimumabClinical trialsIndustry payments1Publications1

Works with

trial sponsors and companies reporting payments
Pfizer Inc.Clinical trialsIndustry payments28E.R. Squibb & Sons, L.L.C.Clinical trialsIndustry payments19Gilead Sciences, Inc.Clinical trialsIndustry payments13

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
817publications

Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.

51,894citations

Total citations across indexed works.

85h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials
21companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2012–2024

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    52.2%
    Serotonin-3 Receptor Antagonist28.7%
    Ondansetron Hcl100%
    Part D13 patients
    Biguanide (metformin)12.2%
    Metformin Hcl Er100%
    Part D<11 patients
  • Genitourinary & hormones

    13.9%
    alpha-Adrenergic Blocker13.9%
    Tamsulosin Hcl100%
    Part D<11 patients
  • Dermatology

    13%
    Corticosteroid13%
    Triamcinolone Acetonide100%
    Part D<11 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20122024 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • ResearchGate

    researchgate.net/scientific-contributions/Jonathan-E-Rosenberg-39327781

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • X / Twitter

    x.com/drrosenbergmsk

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/memorial-sloan-kettering-cancer-center_new-metastatic-bladder-cancer-therapy-approved-activity-7051906684356550656-eS8I

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com
  • Other

    bcan.org/staff/jonathan-e-rosenberg-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org
  • Other

    onclive.com/authors/jonathan-e-rosenberg-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Harvard Medical School

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
  • BA

    Duke University (undergraduate)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org
  • Internal Medicine residency/internship

    NewYork-Presbyterian/Weill Cornell Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
  • Medical Oncology (Hematology/Oncology) Fellowship

    University of California San Francisco Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org

Editorial & leadership roles

journal and society appointments
  • Professor of Medicine

    Weill Cornell Medical College

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu
  • Chief

    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
  • Attending Physician

    Memorial Hospital at Memorial Sloan Kettering Cancer Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org
1 more role behind the reveal.Reveal →

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Cross-Field
    20212022202320242025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.